NCT05497635View on ClinicalTrials.gov

A Study of STSA-1002 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
Healthy Subject
Interventions
DRUG

STSA-1002 Injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Trial Locations (2)

102600

Beijing Shijitan Hospital, Capital Medical University, Beijing

054000

The Second Affiliated Hospital Of Xingtai Medical College, Xingtai

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY